Literature DB >> 16957585

Leukemia inhibitory factor arrests oligodendrocyte death and demyelination in spinal cord injury.

Michael F Azari1, Christos Profyris, Tara Karnezis, Claude C Bernard, David H Small, Surindar S Cheema, Ezgi Ozturk, Irene Hatzinisiriou, Steven Petratos.   

Abstract

As a consequence of secondary pathophysiological mechanisms elicited after spinal cord injury (SCI), oligodendrocytes die by waves of apoptosis. This ultimately results in demyelination of intact axons leading to a loss of their conducting properties. Preservation of as few as 5% to 10% of myelinated axons in individual tracts can confer locomotor recovery. Thus, strategies aimed at rescuing mature oligodendrocytes ensheathing viable axons are likely to be of therapeutic significance. We report that leukemia inhibitory factor (LIF) can prevent oligodendrocyte apoptosis, notably contralateral to the spinal cord lesion, through the induction of the JAK/STAT and Akt signaling pathways as well as by potentiating the expression of the antiapoptotic molecule, cIAP2. Reduced oligodendrocyte apoptosis after SCI with LIF administration resulted in a substantial decrease in demyelination shown by the preservation of lamellated myelin surrounding viable axons and deposition of the degraded myelin basic protein. The data suggest that LIF signals survival in oligodendrocytes after SCI, prevents the secondary wave of demyelination, and thereby reduces inhibitory myelin deposits.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16957585     DOI: 10.1097/01.jnen.0000235855.77716.25

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  28 in total

Review 1.  Oligodendrocyte fate after spinal cord injury.

Authors:  Akshata Almad; F Rezan Sahinkaya; Dana M McTigue
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

2.  Changes in NG2 cells and oligodendrocytes in a new model of intraspinal hemorrhage.

Authors:  F Rezan Sahinkaya; Lindsay M Milich; Dana M McTigue
Journal:  Exp Neurol       Date:  2014-03-11       Impact factor: 5.330

Review 3.  The role of the leukemia inhibitory factor receptor in neuroprotective signaling.

Authors:  Stephanie M Davis; Keith R Pennypacker
Journal:  Pharmacol Ther       Date:  2017-08-19       Impact factor: 12.310

4.  Efficacy of leukemia inhibitory factor as a therapeutic for permanent large vessel stroke differs among aged male and female rats.

Authors:  Stephanie M Davis; Lisa A Collier; Sarah Goodwin; Douglas E Lukins; David K Powell; Keith R Pennypacker
Journal:  Brain Res       Date:  2018-11-13       Impact factor: 3.252

5.  Leukemia inhibitor factor promotes functional recovery and oligodendrocyte survival in rat models of focal ischemia.

Authors:  Derrick D Rowe; Lisa A Collier; Hilary A Seifert; Cortney B Chapman; Christopher C Leonardo; Alison E Willing; Keith R Pennypacker
Journal:  Eur J Neurosci       Date:  2014-07-16       Impact factor: 3.386

6.  An in vivo characterization of trophic factor production following neural precursor cell or bone marrow stromal cell transplantation for spinal cord injury.

Authors:  Gregory W J Hawryluk; Andrea Mothe; Jian Wang; Shelly Wang; Charles Tator; Michael G Fehlings
Journal:  Stem Cells Dev       Date:  2012-02-07       Impact factor: 3.272

7.  Effect of leukemia inhibitory factor on the myelinogenic ability of Schwann-like cells induced from human adipose-derived stem cells.

Authors:  Shahnaz Razavi; Mohammad Mardani; Mohammad Kazemi; Ebrahim Esfandiari; Manizheh Narimani; Abolghasem Esmaeili; Nafiseh Ahmadi
Journal:  Cell Mol Neurobiol       Date:  2012-12-05       Impact factor: 5.046

8.  Constitutively active Akt induces enhanced myelination in the CNS.

Authors:  Ana I Flores; S Priyadarshini Narayanan; Emily N Morse; H Elizabeth Shick; Xinghua Yin; Grahame Kidd; Robin L Avila; Daniel A Kirschner; Wendy B Macklin
Journal:  J Neurosci       Date:  2008-07-09       Impact factor: 6.167

9.  Involvement of ERK2 in traumatic spinal cord injury.

Authors:  Chen-Guang Yu; Robert P Yezierski; Aashish Joshi; Kashif Raza; Yanzhang Li; James W Geddes
Journal:  J Neurochem       Date:  2010-01-12       Impact factor: 5.372

10.  CNS-targeted LIF expression improves therapeutic efficacy and limits autoimmune-mediated demyelination in a model of multiple sclerosis.

Authors:  Helena Slaets; Jerome J A Hendriks; Chris Van den Haute; Frea Coun; Veerle Baekelandt; Piet Stinissen; Niels Hellings
Journal:  Mol Ther       Date:  2010-01-12       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.